Health Condition 1: null- Breast cancer
Conditions
Interventions
Intervention1: Tablet Olanzapine 10mg per orally day 1 to 3: This drug is given from the day of chemotherapy up to day 3 in breast cancer patients receiving doxorubicin 60mg/m2 and cyclophosphamide 60
Sponsors
Mysore medical college ad research institute
Eligibility
Inclusion criteria
Inclusion criteria: 1. Histologically confirmed breast cancer. 2. Chemotherapy naive patients. 3. Not complaining of nausea in the past 24 hours prior to initiation of chemotherapy. 4. Renal and liver function tests of the patients within the normal range 5. Patients with child bearing potential had to have a negative urine pregnancy test
Exclusion criteria
Exclusion criteria: 1. History of seizure disorder 2. Brain Metastasis 3. Treatment with another antipsychotic agent such as risperidone, quetiapine, clozapine, phenothiazine or butyrophenone for 30 days prior to or during protocol therapy. 4. Hypersensitivity to olanzapine 5. History of cardiac arrhythmia 6. Uncontrolled congestive cardiac failure or acute myocardial infarction in the previous 6 months 7. History of diabetes mellitus
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To Compare the efficacy of Aprepitant and Olanzapine in the prevention of Chemotherapy Induced Nausea.Timepoint: Day 1 to day 5 from the start of chemotherapy | — |
Secondary
| Measure | Time frame |
|---|---|
| To Compare the efficacy of Aprepitant and Olanzapine in the prevention of acute and delayed emesisTimepoint: Day 1 to day 5 from the start of chemotherapy | — |
Countries
India
Contacts
Public ContactDr Akshya
Mysore medical college and research institute
Outcome results
None listed